Key facts
- Notable investors include iGrow Venture Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Alvion
- ·The full record, as it builds
Funding rounds
No funding rounds for Alvion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alvion
Manufacturer of pharmaceutical research and manufacturing capabilities intended to develop and supply proprietary and value-added medicines across multiple therapeutic areas. The company offers in-house development of non-infringing generics, a diversified product portfolio across cardiology, diabetes, central nervous system, and urology, and global licensing and supply partnerships, enabling pharmaceutical partners across Europe, MENA, Canada, Australia, South Africa, APAC, LATAM, and the United States to access and distribute medicines through a B2B model that supports scalable market reach.
- Sector
- Healthcare
- HQ
- Athens, Greece
- Founded
- 2013
- Employees
- 20
- Website
- alvionpharma.com/
- Ownership
- Privately Held (backing)
Alvion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alvion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alvion in its N-PORT filings yet. We sweep new filings monthly.